Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Sharon Kleyne Says Love Your Eyes On Air
  • USA - English


News provided by

Bio-Logic Aqua® Research – Water Life Science® -Rogue Media

Dec 29, 2016, 06:00 ET

Share this article

Share toX

Share this article

Share toX

Grants Pass, OR (PRWEB) December 29, 2016 -- Sharon Kleyne, America’s leading water researcher, advocate and host of the nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health on VoiceAmerica, strongly commented on the extravagant claims that other companies are beginning to make about treatments for dry eye disease, which afflicts more than 30 million Americans a year and an astonishing 250 million Chinese each year.

In her recent program, Sharon Kleyne noted that an ever-popular celebrity, after going public with her chronic dry eye symptoms, was quickly signed by a prominent pharmaceutical company as spokesperson for a campaign aimed at increasing education about dry eye disease and rolling out a new product to treat it. The campaign, Eyelove, collects personal stories about chronic dry eye disease. The new product is the first in a new drug class known as lymphocyte function-associated antigen-1 (LFA-1) antagonists.

Sharon Kleyne supports any educational effort to increase awareness about dry eye disease and its symptoms, yet she feels she must also point out the fact that these droplet products—new and old—merely mask symptoms and give only momentary relief. In worst case scenarios, Kleyne said, users can become addicted to drops and solutions and actually make their dry eye conditions even worse. “There is still only one product on the global market,” Kleyne said, that deals with and relieves the root cause of dry eye disease, which is dehydration of the tear film due to excessive evaporation, and that is Natures Tears® EyeMist®. It is the only product with a worldwide patent to supplement the tear film affected by dry eye.

Dry eye disease dwarfs all over diseases that ophthalmologists and optometrists diagnose and treat each year, and the numbers continue to climb with aging populations. Symptoms include blurred vision, redness, burning, itching, stinging, a gritty sensation and watery eyes. These symptoms can be brought on by a number of causes including pollution, allergies, post-menopausal changes in women, windy conditions, computer use, reading, television viewing and artificial environments (air conditioning, central heating). Dry eye disease occurs when the tear film lens, which is 99% water, loses moisture due to evaporation. “The most effective way to relieve dry eye symptoms,” Sharon Kleyne insisted, “is to supplement the eyes several times a day with a painless micron mist of trade secret, tissue culture grade water.” This is more effective than eye drops, which only trap moisture but do not replenish it.

Sharon Kleyne, founder of Bio-Logic Aqua® Research Water Life Science®, researched and developed new technology that has given us just that product—Natures Tears® EyeMist®. Kleyne has earned an international reputation as the global expert on dehydration of the eyes and skin due to excessive evaporation of the body’s water vapor. “From the moment we leave our mother’s water-womb and are born,” Kleyne said, “we begin a process of evaporation that continues until death. In order to sustain excellent health,” she went on, “one must supplement eyes and skin on a daily basis to replenish the evaporating water vapor. Of course, the purer the water is, the better it will be for the person supplementing skin and eyes with it.”

Nature’s Tears® EyeMist® is applied with a personal hand-held humidifying device emitting a pure, pH balanced, 100% Trade Secret tissue culture grade water in a patented micron mist. Nature’s Tears® EyeMist® is endorsed by more than 22,000 ophthalmologists and optometrists nationwide and was successfully test-marketed in more than 70,000 outlets. With Natures Tears® EyeMist®, Sharon Kleyne explains, tired or irritated eyes are supplemented with pure water, and that’s exactly what eyes challenged by dry eye symptoms need. With Nature’s Tears® EyeMist®, Kleyne is sure that the people leaving their stories at Eyelove would find immediate relief, too. “I have some for each of them whenever they are ready!” Kleyne said.

Sharon Kleyne is constantly educating people about the current global water crisis and the health dangers associated with dehydration due to excess evaporation of the earth’s water vapor. In doing so, Kleyne encourages people to experience a new, healthy Water Life Science® lifestyle and visit http://www.biologicaqua.com for more information.

Mikaylah Roggasch, Bio-Logic Aqua® Research – Water Life Science® -Rogue Media, http://www.biologicaqua.com, +1 (800) 367-6478, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.